India · Delayed Price · Currency is INR Venus Remedies Statistics
Total Valuation
Venus Remedies has a market cap or net worth of INR 20.98 billion. The enterprise value is 20.07 billion.
| Market Cap | 20.98B |
| Enterprise Value | 20.07B |
Important Dates
The last earnings date was Monday, July 20, 2026.
| Earnings Date | Jul 20, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Share Statistics
Venus Remedies has 13.37 million shares outstanding. The number of shares has decreased by -0.20% in one year.
| Current Share Class | 13.37M |
| Shares Outstanding | 13.37M |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 29.52% |
| Owned by Institutions (%) | 1.16% |
| Float | 6.41M |
Valuation Ratios
The trailing PE ratio is 18.06.
| PE Ratio | 18.06 |
| Forward PE | n/a |
| PS Ratio | 2.59 |
| PB Ratio | 3.16 |
| P/TBV Ratio | 3.68 |
| P/FCF Ratio | 17.76 |
| P/OCF Ratio | 13.47 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.02, with an EV/FCF ratio of 16.99.
| EV / Earnings | 17.28 |
| EV / Sales | 2.47 |
| EV / EBITDA | 12.02 |
| EV / EBIT | 14.35 |
| EV / FCF | 16.99 |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.07 |
| Debt / FCF | 0.11 |
| Interest Coverage | 4,661.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 18.63% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | 5.58% |
| Revenue Per Employee | 5.51M |
| Profits Per Employee | 789,063 |
| Employee Count | 1,298 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Venus Remedies has paid 354.30 million in taxes.
| Income Tax | 354.30M |
| Effective Tax Rate | 23.37% |
Stock Price Statistics
The stock price has increased by +218.28% in the last 52 weeks. The beta is 0.25, so Venus Remedies's price volatility has been lower than the market average.
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +218.28% |
| 50-Day Moving Average | 1,599.75 |
| 200-Day Moving Average | 958.38 |
| Relative Strength Index (RSI) | 40.52 |
| Average Volume (20 Days) | 4,581 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Venus Remedies had revenue of INR 8.11 billion and earned 1.16 billion in profits. Earnings per share was 86.89.
| Revenue | 8.11B |
| Gross Profit | 4.14B |
| Operating Income | 1.40B |
| Pretax Income | 1.52B |
| Net Income | 1.16B |
| EBITDA | 1.67B |
| EBIT | 1.40B |
| Earnings Per Share (EPS) | 86.89 |
Balance Sheet
The company has 1.03 billion in cash and 124.10 million in debt, with a net cash position of 910.00 million or 68.08 per share.
| Cash & Cash Equivalents | 1.03B |
| Total Debt | 124.10M |
| Net Cash | 910.00M |
| Net Cash Per Share | 68.08 |
| Equity (Book Value) | 6.64B |
| Book Value Per Share | 496.59 |
| Working Capital | n/a |
Cash Flow
In the last 12 months, operating cash flow was 1.56 billion and capital expenditures -376.56 million, giving a free cash flow of 1.18 billion.
| Operating Cash Flow | 1.56B |
| Capital Expenditures | -376.56M |
| Depreciation & Amortization | 271.88M |
| Net Borrowing | -25.30M |
| Free Cash Flow | 1.18B |
| FCF Per Share | 88.36 |
Margins
Gross margin is 51.02%, with operating and profit margins of 17.24% and 14.32%.
| Gross Margin | 51.02% |
| Operating Margin | 17.24% |
| Pretax Margin | 18.68% |
| Profit Margin | 14.32% |
| EBITDA Margin | 20.59% |
| EBIT Margin | 17.24% |
| FCF Margin | 15.35% |
Dividends & Yields
This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.61%.
| Dividend Per Share | 10.00 |
| Dividend Yield | 0.61% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 11.51% |
| Buyback Yield | 0.20% |
| Shareholder Yield | 0.81% |
| Earnings Yield | 5.54% |
| FCF Yield | 5.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |